Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson... ( KENILWORTH N.J. Nov. 24 /- Schering-P...)

Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease

Date:11/24/2008

KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that preladenant, its novel and selective adenosine2a receptor antagonist, met the primary endpoint in a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson's disease experiencing motor fluctuations and abnormal involuntary movements (dyskinesias). The trial results were presented today at the company's 2008 R&D Update meeting being hosted for analysts and portfolio managers at company headquarters.

The dose-finding study was a randomized, placebo-controlled, double-blind, multicenter, multinational clinical trial that evaluated the efficacy and safety of four different doses (1, 2, 5 or 10 mg BID) of preladenant compared to placebo in the treatment of patients with moderate to severe Parkinson's disease with motor fluctuations and dyskinesias. All patients were on a stable regimen of standard treatments with L-DOPA and other adjunctive treatments, such as dopamine agonists and/or entacapone, but were still experiencing motor fluctuations and dyskinesias. The previous treatment was continued throughout the trial, in which the study medication was given as an adjunctive therapy.

A total of 253 patients were randomized into the trial, with the treatment phase lasting 12 weeks. Preladenant was statistically significantly more effective than the control group at the doses of 5 and 10 mg BID, respectively, in reducing the "off"-time, the primary endpoint of the trial.

In addition, preladenant significantly increased the "on"-time at the same doses of 5 and 10 mg BID, a secondary endpoint of the study. Importantly, this improvement in "on"-time was not associated with a proportional overall increase in dyskinesias. Preladenant was found to be safe and well tolerated.
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
2. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
3. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
4. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
5. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
6. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
7. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
8. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
9. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
10. Schering-Plough Reports Top-Line Results of the IDEAL Study
11. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA

Post Your Comments:

Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson...( KENILWORTH N.J. Nov. 24 /- Schering-P...),Health